Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | $66.41M |
| Gross Profit (TTM) | $-428.74M |
| EBITDA | $-501.23M |
| Operating Margin | -1986.00% |
| Return on Equity | -57.20% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $0.14 |
| Book Value | $1.93 |
| Price-to-Book | 1.98 |
| Price-to-Sales (TTM) | 30.69 |
| EV/Revenue | 21.95 |
| EV/EBITDA | -5.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -56.10% |
| Shares Outstanding | $524.68M |
| Float | $512.98M |
| % Insiders | 2.37% |
| % Institutions | 68.85% |
Volatility is currently contracting
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data are based on a small cohort of 16 patients, with the drug only now reaching relevant dose levels for anti-tumor activity, limiting conclusions. A H2 '26 update from DHALIA could confirm anti-tumor activity of REC-1245, but might not have enough additional data to go beyond that.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
